Pseudovirus News and Research

RSS

Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2

A new study analyzed multivalent messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine constructs against certain β-coronaviruses (β-CoVs).

3 May 2022

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

In a new study, researchers described their self-designed chimeric receptor-binding domain-dimer vaccine approach to adapt SARS-CoV-2 variants of concern and variants of interest.

29 Apr 2022

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

28 Apr 2022

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

28 Apr 2022

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.

28 Apr 2022

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Researchers assessed the antibody responses elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and defined the epitopes shared by them.

28 Apr 2022

Nanobody effectively neutralizes pseudotyped ancestral SARS-CoV-2 and Omicron spike proteins

Researchers identified a nanobody inhibiting SARS-CoV-2 variants.

26 Apr 2022

Durability and neutralization capacity of SARS-CoV-2 specific antibodies in the breastmilk of convalescent COVID-19 mothers

The researchers assessed immunological and pathophysiological aspects of antenatal COVID-19.

26 Apr 2022

Cross-reactive coronavirus antibodies might not be cross-neutralizing

In a recent study posted to Research Square* preprint server, researchers reported that cross-reactive antibodies against coronaviruses (CoVs) might not cross-neutralize all CoVs.

25 Apr 2022

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Researchers isolate three mAbs that broadly neutralized sarbecoviruses and carried out virological and structural studies of these mAbs.

21 Apr 2022

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Do a person's antibodies work to block the COVID-19 virus from infecting one's system? Are these antibodies also capable of blocking emerging variants such as the omicrons?

21 Apr 2022

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

ENSEMBLE data was used to evaluate three immune markers as correlates of protection following a single dose of Ad26.COV2.S vaccine.

18 Apr 2022

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Researchers identified drugs inhibiting the entry of SARS-CoV-2.

18 Apr 2022

Monoclonal antibodies from COVID-19 convalescent donors target conserved site

Researchers found six monoclonal antibodies binding to the spike proteins of all human coronaviruses.

18 Apr 2022

Durable neutralizing response against Omicron after heterologous vaccine boosting

Researchers assess the impact of homologous and heterologous primary-booster vaccine dose combinations.

15 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

SARS-CoV-2 spike S375F mutation triggered the explosive spread of Omicron

In a recent study posted to the bioRxiv* preprint server, researchers investigated the mutation in the viral spike (S) protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 variant (referred to as Omicron in the present study) that is responsible for the variant’s virological features.

7 Apr 2022

COVID boosters protect you better than monoclonal antibodies, or natural infection

In a new study published in the journal Science Translational Medicine, researchers analyzed the neutralization of the Omicron BA.1 variant pseudovirus by post-vaccination serum samples.

6 Apr 2022

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

Researchers investigated the effectiveness of a circRNA vaccine against SARS-CoV-2 and its Delta and Omicron variants, which elicited significant antibody and T-cell responses in mice and rhesus macaques.

6 Apr 2022

Pseudovirus News and Research

Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Nanobody effectively neutralizes pseudotyped ancestral SARS-CoV-2 and Omicron spike proteins

Durability and neutralization capacity of SARS-CoV-2 specific antibodies in the breastmilk of convalescent COVID-19 mothers

Cross-reactive coronavirus antibodies might not be cross-neutralizing

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Monoclonal antibodies from COVID-19 convalescent donors target conserved site

Durable neutralizing response against Omicron after heterologous vaccine boosting

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 spike S375F mutation triggered the explosive spread of Omicron

COVID boosters protect you better than monoclonal antibodies, or natural infection

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News